Greenwich Lifesciences: Executive Increases Stake to 5.6 Million Shares!
Reading Time: 1 minute
Greenwich Lifesciences (GLSI) is a clinical-stage biopharmaceutical company focused exclusively on GP2 (GLSI-100). This is an immunotherapy aimed at preventing breast cancer recurrences in patients who have already completed their primary treatment. As a well-tolerated "maintenance therapy," GP2 utilizes a HER2/neu peptide in combination with an immune stimulant to train the immune system to recognize and destroy remaining cancer cells early. Preliminary data from the pivotal Phase III trial "Flamingo-01" showed an approximately 80% reduction...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
